Pegilodecakin alone or in combination for heavily pre-treated advanced kidney cancer patients
This study looked at the use of pegilodecakin alone or [...]
NHS patients could be offered intravenous cancer treatments at home
In an attempt to reduce treatment backlogs and hospital visits, [...]
Immune checkpoint inhibitors for sarcomatoid kidney cancer
Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive [...]
Association of immune-related adverse events and outcomes in kidney cancer
Previous studies have shown that cancer patients who experience immune-related [...]
Patients with autoimmune disorders have more immune-related side effects to immunotherapy
A study published in The Oncologist recently shows that patients [...]
Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer
This Practice Update interview with Dr Monty Pal from City [...]
Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer
Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial [...]
ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer
Results of a retrospective study presented during the 2021 American [...]
ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination
Long-term follow-up data from the CheckMate-214 study of the nivolumab [...]
